Recent Updates
Recently added Catalysts
MIRA Positive Sentiment

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

Thursday, August 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MIRA Pharmaceuticals has reported positive results from a 7-day repeated-dose study of its obesity treatment candidate, SKNY-1, in Beagle dogs. The findings indicate favorable toxicokinetic profiles that aid in dose selection and bolster the company's regulatory pathway towards an Investigational New Drug (IND) application. This advancement marks a significant step for MIRA in developing novel therapeutics.

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive toxicokinetic findings from the study.
  • Supports regulatory pathway toward IND.
  • Demonstrates effective dose selection.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+5%
120-day peak, hindsight
Typical move
0.6%
average across 2 past catalysts
Cash runway
~21 mo
Low dilution risk

Full Press Release Details

Obesity Treatment Candidate Designed to Preserve Lean Body Mass Toxicokinetic Findings De-Risk Dose Selection and Support Regulatory Pathway Toward IND MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) — MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs. The study demonstrates dose-de…
You can read the full content here
The post MIRA Reports Positive 7-Day Dog Study Results for SKNY-1 appeared first on MIRA Pharmaceuticals, Inc. (MIRA) .

Frequently Asked Questions

What were the results of the SKNY-1 dog study?

The study reported positive toxicokinetic findings for SKNY-1 in Beagle dogs.

How does the study support MIRA's regulatory pathway?

The findings aid in dose selection and support the pathway toward an IND application.

What is SKNY-1 designed to treat?

SKNY-1 is designed as an obesity treatment candidate.

What type of dogs were used in the study?

The study was conducted using Beagle dogs.

ShareAdd on Google
Tags: MIRA Viatris Investor Conferences Healthcare MIRA Pharmaceuticals SKNY-1 obesity treatment toxicokinetic findings IND application
Last updated: Aug 6, 2026

Biotech snapshot

Cash runway
$9M liquidity · $0M/mo burn
~21 mo
Low dilution risk

Catalyst track record

+5%
best trade around MIRA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for MIRA.

See every catalyst's timing & PoA →